Patent intelligence Β· CN
CN 105120840
Composition of tiacumicin compounds
Composition of tiacumicin compounds
Patent details β CN 105120840
- Jurisdiction
- CN
- Status
- granted
- Grant date
- Dec 2, 2015
- Expiration
- Nov 27, 2035
- Applicant
- ASTELLAS PHARMA EUROP B V
- CPC classes
- A61K 9/ 00 A I, A61K 9/ 16 A I, A61K 47/ 36 A I, A61K 47/ 38 A I
Quick answer
CN 105120840 (Composition of tiacumicin compounds) is held by ASTELLAS PHARMA EUROP B V. Status: granted. Granted Dec 2, 2015. Expires Nov 27, 2035 (9 years remaining) β relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- ASTELLAS PHARMA EUROP B V
- Grant date
- Expiration
- Claims
- β
- CPC classes
- A61K 9/ 00 A I, A61K 9/ 16 A I, A61K 47/ 36 A I, A61K 47/ 38 A I, A61K/317034, A61K/317048
More from ASTELLAS PHARMA EUROP B V
Related pharmaceutical patents in our USPTO index.
-
CN 120418289
Combination therapy of bispecific binding agents that bind to CLDN18.2 and CD3 with immune checkpoint inhibitors
granted -
KR 20240032847
CLDN18.2 λ° CD3μ κ²°ν©νλ μ΄μ€νΉμ΄ κ²°ν©μ
granted -
EP 1549658
VERBINDUNGEN AUF GLUKOSEBASIS MIT AFFINITΓT FΓR P-SELEKTIN
expired -
EP 1527086
VERBINDUNGEN DIE P-SELECTIN BINDEN
expired -
EP 1423413
SELEKTIV P-SELECTIN BINDENDE PEPTIDISCHE VERBINDUNGEN
expired -
EP 1392755
ZUSAMMENSETZUNGEN ENTHALTEND LIPID-POLYMER KONJUGATE
expired -
IS 5505
Notkun Γ‘ blΓΆndu dΓΓ³ls og alfa-hΓ½droxΓ½sΓ½ru til aΓ° meΓ°hΓΆndla sjΓΊkdΓ³ma sem lΓ½sa sΓ©r Γ ofvexti Γ hornlagi húðþekju
expired
Frequently asked questions
What is US patent 105120840?
CN 105120840 (Composition of tiacumicin compounds) is held by ASTELLAS PHARMA EUROP B V. Status: granted. Granted Dec 2, 2015. Expires Nov 27, 2035 (9 years remaining) β relevant for patent-cliff and LOE planning.
Who owns CN 105120840?
ASTELLAS PHARMA EUROP B V is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 10 pharmaceutical patents for this assignee.
When does CN 105120840 expire?
Our index shows an expiration date of Nov 27, 2035 (9 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.